TYPE 2 COMORBIDITIES IN PATIENTS INITIATING DUPILUMAB FOR ASTHMA: REAL-WORLD EVIDENCE FROM A NATIONAL US DATABASE
Author(s)
Nella Bieszk, PharmD1, Anne-Laure Tardy, PhD2, Richard H. STANFORD, MS, PharmD3, Robert Lubwama, PhD4, Joe Yang, PhD5, Rachel Parry, PharmD, PhD6, Vincent J. Willey, PharmD6, Chia-Chen Teng, MS6, Brian Benett, MBA, MS6, M.S. Blaiss, MD, FACAAI, FAAAAI7;
1Sanofi, Cambridge, MA, USA, 2Sanofi, Gentilly, France, 3AESARA Inc., Chapel Hill, NC, USA, 4Sanofi, Morristown, NJ, USA, 5Regeneron Pharmaceuticals, Inc., Sleepy Hollow, NY, USA, 6Carelon Research, Wilmington, DE, USA, 7Medical College of Georgia at Augusta University, Augusta, GA, USA
1Sanofi, Cambridge, MA, USA, 2Sanofi, Gentilly, France, 3AESARA Inc., Chapel Hill, NC, USA, 4Sanofi, Morristown, NJ, USA, 5Regeneron Pharmaceuticals, Inc., Sleepy Hollow, NY, USA, 6Carelon Research, Wilmington, DE, USA, 7Medical College of Georgia at Augusta University, Augusta, GA, USA
OBJECTIVES: Dupilumab received its first US FDA approval in 2017 for atopic dermatitis, followed by approval for moderate-to-severe asthma with type 2 (T2) inflammation in 2018. Subsequently, the indications for dupilumab currently include several T2 conditions. The Global Initiative for Asthma guidelines highlight the importance of considering comorbid T2 driven conditions when selecting biologics. This study aims to characterize asthma patients initiating dupilumab in the current US clinical setting.
METHODS: This retrospective cohort study used claims data from the Healthcare Integrated Research Database to identify patients with asthma aged ≥12 years who initiated dupilumab (index date) between October 2021 and July 2024. Patients were included if they had received at least one medium- or high-dose ICS fill in the pre-index period (12 months before index) and had 12 months of continuous enrollment before and after the dupilumab initiation. Patient characteristics including demographic, socioeconomic status (SES), and clinical profile including T2 comorbidities were recorded during the 12-month pre-index period and were summarized descriptively.
RESULTS: A total of 3,018 patients (59.9% female) were included in the analysis. Patients were mostly White (74.2%) and aged 47.7 [SD: 16.1] years (30.5% aged 18-39 years and 51.9% aged 40-64 years). Patients with available neighborhood SES data (n=2,746) were distributed across quartiles as follows: 13.8% (lowest), 23.2%, 26.9%, and 36.1% (highest). Additionally, 86.6% of patients were biologic-naïve. Dupilumab was prescribed most commonly by allergists (36.6%) and pulmonologists (24.0%). The most common T2 inflammatory comorbidities were allergic rhinitis (70.3%), chronic rhinosinusitis with nasal polyps (28.1%), chronic obstructive pulmonary disease (18.3%), atopic dermatitis (17.5%) and eosinophilic esophagitis (9.5%). Other comorbidities included hypertension (39.2%) and anxiety (28.8%).
CONCLUSIONS: Real-world data revealed that patients initiating dupilumab had substantial T2 inflammatory comorbidities, highlighting the need for better integrated care management strategies. Higher neighborhood SES could imply potential disparities in care access.
METHODS: This retrospective cohort study used claims data from the Healthcare Integrated Research Database to identify patients with asthma aged ≥12 years who initiated dupilumab (index date) between October 2021 and July 2024. Patients were included if they had received at least one medium- or high-dose ICS fill in the pre-index period (12 months before index) and had 12 months of continuous enrollment before and after the dupilumab initiation. Patient characteristics including demographic, socioeconomic status (SES), and clinical profile including T2 comorbidities were recorded during the 12-month pre-index period and were summarized descriptively.
RESULTS: A total of 3,018 patients (59.9% female) were included in the analysis. Patients were mostly White (74.2%) and aged 47.7 [SD: 16.1] years (30.5% aged 18-39 years and 51.9% aged 40-64 years). Patients with available neighborhood SES data (n=2,746) were distributed across quartiles as follows: 13.8% (lowest), 23.2%, 26.9%, and 36.1% (highest). Additionally, 86.6% of patients were biologic-naïve. Dupilumab was prescribed most commonly by allergists (36.6%) and pulmonologists (24.0%). The most common T2 inflammatory comorbidities were allergic rhinitis (70.3%), chronic rhinosinusitis with nasal polyps (28.1%), chronic obstructive pulmonary disease (18.3%), atopic dermatitis (17.5%) and eosinophilic esophagitis (9.5%). Other comorbidities included hypertension (39.2%) and anxiety (28.8%).
CONCLUSIONS: Real-world data revealed that patients initiating dupilumab had substantial T2 inflammatory comorbidities, highlighting the need for better integrated care management strategies. Higher neighborhood SES could imply potential disparities in care access.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD164
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Biologics & Biosimilars